Shares of Torrent Pharmaceuticals rallied more than 4% in early trade on Monday after the company announced its financial results for the quarter ended March 2026.
The pharmaceutical company reported a consolidated net profit of Rs 389 crore in Q4, down 21.9% compared to Rs 498 crore in the corresponding quarter last year. The decline in profit came amid higher exceptional losses during the quarter.
Torrent Pharma said it recorded a one-time loss of Rs 66 crore in Q4, compared to a loss of Rs 24 crore reported in the year-ago period.
Despite the decline in net profit, the company posted robust growth in revenue and operating profit. Revenue from operations rose 41.8% year-on-year to Rs 4,197 crore, compared to Rs 2,959 crore reported in the same quarter last year.
The company’s EBITDA increased 40.7% to Rs 1,356 crore versus Rs 964 crore in the corresponding quarter of the previous financial year.
EBITDA margin stood at 32.3% in Q4, slightly lower than 32.6% reported a year ago.
In the meantime, Brokerage firm Jefferies signed a “Buy” rating on Torrent Pharma with a target price of Rs 5,350 following the quarterly results.
According to Jefferies, the March quarter included two months of JB Pharma integration. The brokerage noted that on a like-for-like basis, Torrent Pharma’s results were largely in line with estimates.
Jefferies also highlighted that the company’s India business continued its strong growth momentum, posting 15% year-on-year growth during the quarter. Torrent Pharma expects FY27 to remain a similar or better growth year for its domestic business.
The brokerage further stated that the integration of JB Chemicals & Pharmaceuticals remains on track.
Torrent Pharma Share Price Performance (as of 9:48 AM)
Torrent Pharma shares opened at Rs 4,525 against the previous close of Rs 4,486.20. During the session, the stock touched an intraday high of Rs 4,675 and a low of Rs 4,510.
The stock has recorded a 52-week low of Rs 3,102, while the 52-week high stands at Rs 4,675.